Clinical Trial

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

Final Phase 1b data for Kodiak Sciences' KSI-101 suggests a potential breakthrough for macular edema, a condition lacking dedicated biologic therapies.

A new six-month injection for Central Precocious Puberty shows strong safety and efficacy, promising to ease the treatment burden for children and families.

As the FDA embraces advanced Bayesian statistics, MedTech firm BioStem sees validation for its wound care research, promising faster innovation for patients.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

A new brand claims its decadent milkshakes improve gut health and mood, using invisible science to challenge the war between pleasure and well-being.

A major multi-vendor study confirms AI's power for precision HER2 scoring, promising to improve diagnostics and accelerate personalized cancer therapies.

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

New multi-year data for Fabry and Pompe disease therapies from Amicus Therapeutics showcases sustained benefits, offering new hope for long-term patient outcomes.